ArticleOptometry and vision science : official publication of the American Academy of Optometry2013
Nitric oxide synthase inhibitors prevent the growth-inhibiting effects of quinpirole.
Article in Optometry and vision science : official publication of the American Academy of Optometry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- Topical review: Potential mechanisms of atropine for myopia control.Optometry and vision science : official publication of the American Academy of Optometry · 2025Review
- The Effects of Nitric Oxide on Choroidal Gene Expression.Journal of bioinformatics and systems biology : Open access · 2024Article
- Single Cell Transcriptomics Identifies Distinct Choroid Cell Populations Involved in Visually Guided Eye Growth.Frontiers in ophthalmology · 2023Article
- Efficacy of atropine for myopia control in children: A meta-analysis of randomized controlled trials.Journal of family medicine and primary care · 2022Review
- Choroidal Thickness in Early Postnatal Guinea Pigs Predicts Subsequent Naturally Occurring and Form-Deprivation Myopia.Investigative ophthalmology & visual science · 2022Article
- The choroid-sclera interface: An ultrastructural study.Heliyon · 2022Article
- The Role of Atropine in Preventing Myopia Progression: An Update.Pharmaceutics · 2022Review
- Article
- Ocular Penetrance and Safety of the Dopaminergic Prodrug Etilevodopa.Translational vision science & technology · 2021Article
- Functional integration of eye tissues and refractive eye development: Mechanisms and pathways.Experimental eye research · 2021Review
- The role of dopamine in eye growth responses to color and luminance flicker in chicks.Experimental eye research · 2019Article
- Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way.Trends in pharmacological sciences · 2019Review
- AlphaClinical & experimental optometry · 2019Article
- IMI - Report on Experimental Models of Emmetropization and Myopia.Investigative ophthalmology & visual science · 2019Review
- Short-Term Effect of Low-Dose Atropine and Hyperopic Defocus on Choroidal Thickness and Axial Length in Young Myopic Adults.Journal of ophthalmology · 2019Article
- The effect of unilateral disruption of the centrifugal visual system on normal eye development in chicks raised under constant light conditions.Brain structure & function · 2017Article
- Intravitreally-administered dopamine D2-like (and D4), but not D1-like, receptor agonists reduce form-deprivation myopia in tree shrews.Visual neuroscience · 2017Article
- Nitric Oxide (NO) Mediates the Inhibition of Form-Deprivation Myopia by Atropine in Chicks.Scientific reports · 2016Article
- Oxidative stress in myopia.Oxidative medicine and cellular longevity · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
purposeBoth dopamine and nitric oxide (NO) have been implicated in the signal cascade mediating ocular growth inhibition. If both are part of the same pathway, which precedes the other? We tested the hypothesis that dopamine acts upstream of NO, by using two NOS inhibitors in combination with the dopamine agonist quinpirole, and measured the effects on ocular growth rate.
methodsChicks wore -10 D lenses or diffusers (FD) for 4 days starting at age 13 days. Experimental eyes received daily 20 μL injections of the following: quinpirole-lens: n = 12, FD: n = 20; n-ω-propyl-L-arginine (NPA)-lens: n = 6, FD: n = 4; quinpirole + NPA-lens: n = 17, FD: n = 19; and quinpirole + L-NIO-lens: n = 12, FD: n = 12. Saline injections were done as controls. High-frequency ultrasonography was done at the start, and on day 5, prior to injections and 3 hours later. Refractions were measured on day 5.
resultsAs expected, quinpirole prevented the development of axial myopia in both paradigms. When quinpirole was combined with either NOS inhibitor, however, eyes became myopic compared to quinpirole (FD: NPA: -5.9 D vs. -3.4 D; L-NIO: -5.8 D vs. -3.4 D; lens: NPA: -3.5 D vs. -0.4 D; p < 0.05 for all; L-NIO was not significant). This was the result of a disinhibition of vitreous chamber growth versus quinpirole (FD: NPA: 401 vs. 275 μm/4 d; L-NIO: 440 vs. 275 μm/4 d; LENS: NPA: 407 vs. 253µm/4 d; L-NIO: 403 vs. 253 μm/4 d; p < 0.05). Only NPA prevented the quinpirole-induced choroidal thickening in lens-wearing eyes (0 vs. 31 μm/3 h; p < 0.05). Choroidal thickening was not inhibited by either drug in FD eyes.
conclusionsDopamine acts upstream of NO and the choroidal response in the signal cascade mediating ocular growth inhibition in both form deprivation and negative lens wear. That neither NOS inhibitor inhibits choroidal thickening in FD eyes suggests that the choroidal mechanisms differ in the two paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.